Perinatal Substance Abuse Program (PSAP)

Evaluating Perinatal Substance Abuse Program (PSAP) (San Jose, CA): The facility's programming is outpatient (IOP, MAT), not residential. The structural dimensions to verify — state licensure, voluntary accreditation, clinical-framework alignment with ASAM 4e — are each independently checkable and worth doing before admission rather than after.

Care levels at Perinatal Substance Abuse Program (PSAP)

Perinatal Substance Abuse Program (PSAP) is an outpatient-focused program (IOP, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. ASAM Criteria 4e is the benchmark framework for matching patients to appropriate intensity. Most major payer medical-necessity documents reference it. An outside ASAM-aligned assessment, prior to admission, is the protection against misplacement.

Insurance and payment

Perinatal Substance Abuse Program (PSAP) accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. The facility also accepts TRICARE or military benefits. The operational prerequisite is written documentation: in-network status for your specific plan product, deductible accumulation, coinsurance rate, prior-authorization status. Admissions without these four documented carry material risk of post-admission financial disagreement.

Specialty programming

The facility's documented specialty programming includes: Adolescents, Young adults, Adult women. Specialty designations benefit from specific follow-up: programming hours per week, credentialed staff profile, integrated assessment protocols. Dual-diagnosis as a marketing category differs from operational specialty infrastructure.

Before you call

Three pre-admission questions for Perinatal Substance Abuse Program (PSAP): (1) at what ASAM 4e level are you admitting me, and what is the clinical rationale; (2) can you provide written Verification of Benefits for my specific plan; (3) what is your MAT policy for opioid use disorder — specifically, do you continue buprenorphine or methadone during residential programming. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.